A Phase Ib Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity-Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma.

Lara A Dunn,Nadeem Riaz,Matthew G Fury,Sean M McBride,Loren Michel,Nancy Y Lee,Eric J Sherman,Shrujal S Baxi,Sofia S Haque,Nora Katabi,Richard J Wong,Han Xiao,Alan L Ho,David G Pfister

International Journal of Radiation Oncology*Biology*Physics（2020）

引用 44|浏览75

暂无评分

摘要

The recommended phase II dose of BYL719 is 250 mg/day in combination with cetuximab and IMRT in patients with locally advanced HNSCC. Further evaluation of the addition of BYL719 to the platinum-sparing regimen of cetuximab and IMRT in the treatment of locally advanced HNSCC is warranted.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要